血管免疫母细胞性T细胞淋巴瘤:多面性淋巴瘤
血管免疫母细胞性T细胞淋巴瘤(AITL)是成熟外周T细胞淋巴瘤(PTCL)的少见亚型,常表现为晚期疾病伴非典型实验室和自身免疫学发现,诊断常被延迟或掩盖。2016年世界卫生组织分类将其归入伴滤泡性T辅助表型的淋巴结T细胞淋巴瘤。诱导策略聚焦提高完全缓解率以使更多患者适合移植,复发或难治性AITL的治疗仍是未满足的需求。
要点
- AITL常为晚期疾病,伴非典型实验室和自身免疫学发现,可延迟或掩盖诊断。
- 2016年WHO分类将AITL归入伴滤泡性T辅助表型的淋巴结T细胞淋巴瘤。
- 诱导策略聚焦提高完全缓解率以增加移植资格,复发或难治性AITL治疗仍是未满足需求。
核心结论
- AITL从诊断到治疗的全谱系综述可能最终导向多面性疾病的个体化治疗。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- AITL是成熟外周T细胞淋巴瘤(PTCL)的少见亚型。
- 晚期疾病常见,伴非典型实验室和自身免疫学发现,常延迟或掩盖诊断。
- 免疫组化和分子特征的显著进展提高了诊断AITL的能力。
- 2016年世界卫生组织淋巴样肿瘤分类新增其他AITL样亚型,并将AITL归入伴滤泡性T辅助表型的淋巴结T细胞淋巴瘤。
- 诱导策略继续聚焦提高完全缓解率,使更多适合移植的患者接受巩固性高剂量治疗和自体干细胞救援,以改善长期生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Angioimmunoblastic T-cell lymphoma (AITL) is an uncommon subtype of mature peripheral T-cell lymphoma (PTCL). The history of AITL is much longer and deeper than the literature would suggest given the many names that have preceded it. Advanced-stage disease is common with uncharacteristic laboratory and autoimmune findings that often slow or mask the diagnosis. Significant strides in the immunohistochemical and molecular signature of AITL have brought increased ability to diagnose this uncommon type of PTCL. The 2016 World Health Organization classification of lymphoid neoplasms recently acknowledged the complexity of this diagnosis with the addition of other AITL-like subsets. AITL now resides under the umbrella of nodal T-cell lymphomas with follicular T helper phenotype. Induction strategies continue to focus on increasing complete remission rates that allow more transplant-eligible patients to proceed toward consolidative high-dose therapy and autologous stem cell rescue with improving long-term survival. There are several clinical trials in which recently approved drugs with known activity in AITL are paired with induction regimens with the hope of demonstrating long-term progression-free survival over cyclophosphamide, doxorubicin, vincristine, and prednisone. The treatment of relapsed or refractory AITL remains an unmet need. The spectrum of AITL from diagnosis to treatment is reviewed subsequently in a fashion that may one day lead to personalized treatment approaches in a many-faced disease.
引用
- Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood. 2017. PMID: 28115369. doi:10.1182/blood-2016-09-692541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。